Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Nutrients ; 11(4)2019 Apr 12.
Article in English | MEDLINE | ID: mdl-31013737

ABSTRACT

The innate immune response plays an important role in the pathophysiology of acute respiratory distress syndrome (ARDS). Glutamine (Gln) decreases lung inflammation in experimental ARDS, but its impact on the formation of extracellular traps (ETs) in the lung is unknown. In a mouse model of endotoxin-induced pulmonary ARDS, the effects of Gln treatment on leukocyte counts and ET content in bronchoalveolar lavage fluid (BALF), inflammatory profile in lung tissue, and lung morphofunction were evaluated in vivo. Furthermore, ET formation, reactive oxygen species (ROS) production, glutathione peroxidase (GPx), and glutathione reductase (GR) activities were tested in vitro. Our in vivo results demonstrated that Gln treatment reduced ET release (as indicated by cell-free-DNA content and myeloperoxidase activity), decreased lung inflammation (reductions in interferon-γ and increases in interleukin-10 levels), and improved lung morpho-function (decreased static lung elastance and alveolar collapse) in comparison with ARDS animals treated with saline. Moreover, Gln reduced ET and ROS formation in BALF cells stimulated with lipopolysaccharide in vitro, but it did not alter GPx or GR activity. In this model of endotoxin-induced pulmonary ARDS, treatment with Gln reduced pulmonary functional and morphological impairment, inflammation, and ET release in the lung.


Subject(s)
Extracellular Traps/metabolism , Glutamine/therapeutic use , Inflammation/drug therapy , Lung/drug effects , Pneumonia/drug therapy , Respiratory Distress Syndrome/drug therapy , Animals , DNA , Disease Models, Animal , Endotoxins , Female , Glutamine/pharmacology , Glutathione Peroxidase/metabolism , Glutathione Reductase/metabolism , Inflammation/etiology , Interferon-gamma/metabolism , Interleukin-10/metabolism , Leukocyte Count , Lung/metabolism , Lung/pathology , Male , Mice, Inbred BALB C , Peroxidase/metabolism , Pneumonia/etiology , Pulmonary Alveoli , Reactive Oxygen Species/metabolism , Respiratory Distress Syndrome/metabolism , Respiratory Distress Syndrome/pathology
2.
Front Immunol ; 9: 901, 2018.
Article in English | MEDLINE | ID: mdl-29760707

ABSTRACT

Neutrophils are the first cells of our immune system to arrive at the site of inflammation. They release cytokines, e.g., chemokines, to attract further immune cells, but also actively start to phagocytose and kill pathogens. In the case of sepsis, this tightly regulated host defense mechanism can become uncontrolled and hyperactive resulting in severe organ damage. Currently, no effective therapy is available to fight sepsis; therefore, novel treatment targets that could prevent excessive inflammatory responses are warranted. Src Family tyrosine Kinases (SFK), a group of tyrosine kinases, have been shown to play a major role in regulating immune cell recruitment and host defense. Leukocytes with SFK depletion display severe spreading and migration defects along with reduced cytokine production. Thus, we investigated the effects of dasatinib, a tyrosine kinase inhibitor, with a strong inhibitory capacity on SFKs during sterile inflammation and polymicrobial sepsis in mice. We found that dasatinib-treated mice displayed diminished leukocyte adhesion and extravasation in tumor necrosis factor-α-stimulated cremaster muscle venules in vivo. In polymicrobial sepsis, sepsis severity, organ damage, and clinical outcome improved in a dose-dependent fashion pointing toward an optimal therapeutic window for dasatinib dosage during polymicrobial sepsis. Dasatinib treatment may, therefore, provide a balanced immune response by preventing an overshooting inflammatory reaction on the one side and bacterial overgrowth on the other side.


Subject(s)
Dasatinib/pharmacology , Neutrophil Infiltration/drug effects , Protein Kinase Inhibitors/pharmacology , Sepsis/immunology , Animals , Cell Adhesion/drug effects , Disease Models, Animal , Male , Mice , src-Family Kinases/antagonists & inhibitors
3.
Cell Physiol Biochem ; 38(2): 821-35, 2016.
Article in English | MEDLINE | ID: mdl-26905925

ABSTRACT

BACKGROUND/AIMS: Exogenous surfactant has been proposed as adjunctive therapy for acute respiratory distress syndrome (ARDS), but it is inactivated by different factors present in the alveolar space. We hypothesized that co-administration of LASSBio596, a molecule with significant anti-inflammatory properties, and exogenous surfactant could reduce lung inflammation, thus enabling the surfactant to reduce edema and improve lung function, in experimental ARDS. METHODS: ARDS was induced by cecal ligation and puncture surgery in BALB/c mice. A sham-operated group was used as control (CTRL). After surgery (6 hours), CTRL and ARDS animals were assigned to receive: (1) sterile saline solution; (2) LASSBio596; (3) exogenous surfactant or (4) LASSBio596 plus exogenous surfactant (n = 22/group). RESULTS: Regardless of exogenous surfactant administration, LASSBio596 improved survival rate and reduced collagen fiber content, total number of cells and neutrophils in PLF and blood, cell apoptosis, protein content in BALF, and urea and creatinine levels. LASSBio596 plus surfactant yielded all of the aforementioned beneficial effects, as well as increased BALF lipid content and reduced surface tension. CONCLUSION: LASSBio596 exhibited major anti-inflammatory and anti-fibrogenic effects in experimental sepsis-induced ARDS. Its association with surfactant may provide further advantages, potentially by reducing surface tension.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Biological Products/therapeutic use , Lung/drug effects , Phthalic Acids/therapeutic use , Pulmonary Surfactants/therapeutic use , Respiratory Distress Syndrome/drug therapy , Sulfonamides/therapeutic use , Animals , Apoptosis/drug effects , Lung/immunology , Lung/pathology , Male , Mice, Inbred BALB C , Respiratory Distress Syndrome/immunology , Respiratory Distress Syndrome/pathology , Surface Tension/drug effects
4.
Shock ; 41(3): 222-32, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24430537

ABSTRACT

Malnutrition is a risk factor for infection, compromising immune response. Glutamine (Gln) protects the lungs and distal organs in well-nourished septic and nonseptic conditions; however, no study to date has analyzed the effects of Gln in the presence of sepsis and malnutrition. In the present work, we tested the hypothesis that early therapy with intravenous Gln prevents lung and distal organ damage in septic malnourished rats. Protein-energy malnutrition was induced in male Wistar rats for 4 weeks. At the end of 4 weeks, malnourished animals were assigned to a sepsis-inducing cecal ligation and puncture group or a sham surgery group. One hour after surgery, animals were given saline (Sal) or L-alanyl-L-glutamine (Gln) intravenously. In addition, a control group (C) was set up with rats fed ad libitum, not submitted to surgery or treatment. Forty-eight hours after surgery, in malnutrition-sham rats, Gln therapy lessened neutrophil lung infiltration and apoptosis in lung and liver. In malnutrition-cecal ligation and puncture rats, Gln therapy yielded (a) reduced static lung elastance, alveolar collapse, inflammation (neutrophil infiltration, interleukin 6), and collagen deposition; (b) repair of types I and II epithelial cells; (c) no significant changes in heat shock protein 70 expression or heat shock factor 1 phosphorylation; (d) a greater number of M1 and M2 macrophages in lung tissue; and (e) less apoptosis in the lung, kidney, small intestine, and liver. In conclusion, early therapy with intravenous Gln reduced inflammation, fibrosis, and apoptosis, minimizing lung and distal organ injury, in septic malnourished rats. These beneficial effects may be associated with macrophage activation in the lung.


Subject(s)
Glutamine/administration & dosage , Lung Injury/drug therapy , Malnutrition/drug therapy , Multiple Organ Failure/drug therapy , Sepsis/drug therapy , Administration, Intravenous , Animals , Gene Expression Regulation/drug effects , Inflammation/blood , Inflammation/drug therapy , Inflammation/pathology , Inflammation Mediators/blood , Lung Injury/blood , Lung Injury/etiology , Lung Injury/pathology , Male , Malnutrition/blood , Malnutrition/complications , Malnutrition/pathology , Multiple Organ Failure/blood , Multiple Organ Failure/etiology , Multiple Organ Failure/pathology , Rats , Rats, Wistar , Sepsis/blood , Sepsis/complications , Sepsis/pathology
5.
Respir Physiol Neurobiol ; 189(3): 484-90, 2013 Dec 01.
Article in English | MEDLINE | ID: mdl-24012992

ABSTRACT

We compared the effects of oleanolic acid (OA) vs. dexamethasone on lung mechanics and histology, inflammation, and apoptosis in lung and distal organs in experimental sepsis. Seventy-eight BALB/c mice were randomly divided into two groups. Sepsis was induced by cecal ligation and puncture, while the control group underwent sham surgery. 1h after surgery, all animals were further randomized to receive saline (SAL), OA and dexamethasone (DEXA) intraperitoneally. Both OA and DEXA improved lung mechanics and histology, which were associated with fewer lung neutrophils and less cell apoptosis in lung, liver, and kidney than SAL. However, only animals in the DEXA group had lower levels of interleukin (IL)-6 and KC (murine analog of IL-8) in bronchoalveolar lavage fluid than SAL animals. Conversely, OA was associated with lower inducible nitric oxide synthase expression and higher superoxide dismutase than DEXA. In the experimental sepsis model employed herein, OA and DEXA reduced lung damage and distal organ apoptosis through distinct anti-inflammatory mechanisms.


Subject(s)
Acute Lung Injury/drug therapy , Anti-Inflammatory Agents/therapeutic use , Apoptosis/drug effects , Lung/pathology , Oleanolic Acid/therapeutic use , Oxidative Stress/drug effects , Acute Lung Injury/etiology , Acute Lung Injury/pathology , Animals , Catalase/genetics , Catalase/metabolism , Dexamethasone/therapeutic use , Disease Models, Animal , Gene Expression Regulation/drug effects , Glutathione Peroxidase/genetics , Glutathione Peroxidase/metabolism , Lung/drug effects , Lung/physiology , Male , Mice , Mice, Inbred BALB C , NF-E2-Related Factor 2/genetics , NF-E2-Related Factor 2/metabolism , Nitric Oxide Synthase Type II/genetics , Nitric Oxide Synthase Type II/metabolism , Sepsis/complications , Sepsis/drug therapy , Superoxide Dismutase/genetics , Superoxide Dismutase/metabolism
6.
Shock ; 39(4): 389-96, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23481491

ABSTRACT

A reduction of the neutrophil migration into the site of infection during cecal ligation and puncture-induced sepsis increases host mortality. Inhibition of heme oxygenase (HO) prevents this neutrophil paralysis and improves host survival in the cecal ligation and puncture model. Taking into account that almost 50% of all sepsis cases are a consequence of pneumonia, we designed the present study to determine the role of HO in an experimental model of pneumonia-induced sepsis. The objective of this study was to evaluate whether the inhibition of HO improves the outcome and pathophysiologic changes of sepsis induced by an intratracheal instillation of Klebsiella pneumoniae. The pretreatment of mice subjected to pneumonia-induced sepsis with ZnDPBG (zinc deuteroporphyrin 2,4-bis glycol), a nonspecific HO inhibitor, increased the number of neutrophils in the bronchoalveolar spaces, reduced the bacterial load at the site of infection, and prevented the upregulation of CD11b and the downregulation of CXCR2 on blood neutrophils. Moreover, the pretreatment with ZnDPBG decreased alveolar collapse, attenuating the deleterious changes in pulmonary mechanics and gas exchanges and, as a consequence, improved the survival rate of mice from 0% to ∼20%. These results show that heme oxygenase is involved in the pathophysiology of pneumonia-induced sepsis and suggest that HO inhibitors could be helpful for the management of this disease.


Subject(s)
Bacteremia/enzymology , Heme Oxygenase (Decyclizing)/antagonists & inhibitors , Immune System Diseases/enzymology , Klebsiella Infections/enzymology , Leukocyte Disorders/enzymology , Pneumonia, Bacterial/enzymology , Pulmonary Alveoli/enzymology , Acute Lung Injury/prevention & control , Animals , Bacteremia/microbiology , Bronchi/enzymology , Chemokines/metabolism , Creatine Kinase, MB Form/metabolism , Cytokines/metabolism , Deuteroporphyrins/pharmacology , Enzyme Inhibitors/pharmacology , Klebsiella Infections/microbiology , Klebsiella pneumoniae , Mice , Pneumonia, Bacterial/microbiology , Receptors, Interleukin-8B/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...